Dayvigo (Lemborexant) Safety in Adults 65 and Older
Evidence-based review of lemborexant (Dayvigo) safety in geriatric patients 65+, covering fall risk, next-day sedation, drug interactions, dosing, and deprescribing from SUNRISE clinical trials.
Lemborexant
13 source-based articles maintained by the HealthRX.com Editorial Team.
13articles
6topic areas covered
May 25, 2026latest review
Lemborexant library
Showing 13 of 13 clinical reviews.
Dayvigo (Lemborexant) Safety in Adults Aged 30 to 49: What the Evidence Shows
A guide to lemborexant (Dayvigo) safety for adults aged 30 to 49, covering adverse effects, next-day function, drug interactions, and what the FDA label and trial literature do and do not establish.
Dayvigo (Lemborexant) Storage, Stability & Shelf Life
FDA-backed guidance on storing Dayvigo (lemborexant) tablets, including temperature ranges, shelf life, light sensitivity, and what happens when storage conditions are compromised.
Dayvigo Cost vs. Alternatives: Comparing Lemborexant to Other Insomnia Treatments
A detailed comparison of Dayvigo (lemborexant) pricing, efficacy, and safety against suvorexant, generic Z-drugs, and other insomnia medications, with trial data and practical guidance.
Dayvigo Food & Supplement Interactions: What to Avoid With Lemborexant
A guide to lemborexant (Dayvigo) food and supplement interactions, covering grapefruit, alcohol, melatonin, valerian, and CYP3A4 inhibitors, with PubMed-cited evidence and dosing guidance.
Dayvigo Hair and Skin Changes: What the Evidence Actually Shows
Does lemborexant (Dayvigo) cause hair loss or skin changes? A deep dive into the pharmacology, clinical trial data, and post-marketing reports to help you weigh the real risks.
Dayvigo Half-Life: 17-19 Hours and Missed-Dose Rule
Dayvigo's half-life is 17 to 19 hours. Missed a dose? Take it only with 7+ hours of sleep time left, otherwise skip and resume the next night.
Dayvigo Mental Health and Mood Impact: What the Evidence Shows
A clinician-level review of lemborexant (Dayvigo) and its effects on mood, anxiety, depression, and next-day cognitive function, drawing on SUNRISE-1, FDA labeling, and current sleep-psychiatry literature.
Dayvigo Rebound Effects When Stopping: What the Clinical Evidence Actually Shows
An evidence-based guide to lemborexant (Dayvigo) rebound insomnia and discontinuation effects, covering mechanism, trial evidence, tapering strategies, and when to seek clinical support.
Dayvigo Switching Protocols: How to Switch From or To Lemborexant Safely
A guide to switching from zolpidem, eszopiclone, suvorexant, or other sleep medications to lemborexant (Dayvigo), covering mechanism, pharmacology, tapering considerations, and the evidence behind them.
Does Blue Cross Blue Shield Cover Dayvigo (Lemborexant)?
Find out whether Blue Cross Blue Shield plans cover Dayvigo (lemborexant) for insomnia, including formulary tier, prior authorization requirements, step therapy, and how to appeal a denial.
Is Dayvigo a Controlled Substance? Schedule IV Explained
Yes, Dayvigo (lemborexant) is a Schedule IV controlled substance. See why, plus its boxed warning, approved doses, and key FDA safety signals.
Is Dayvigo Available in the UK? Regulatory Status Explained
Dayvigo (lemborexant) is not approved by the UK's MHRA or EU's EMA as of mid-2024, though it holds FDA and Health Canada approval. See full status details.